Amanote Research
Register
Sign In
P1.01-55 Unique Genetic Profiles From Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC With Leptomeningeal Metastases
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.611
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
Y. Li
B. Jiang
M. Zheng
H. Tu
J.-. Yang
X. Zhang
J. Ye
Q. Zhou
W. Zhong
C. Zhang
S. Chuai
Y. Wu
Publisher
Elsevier BV
Related search
P1.01-100 Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients With Brain Metastases From EGFR-Mutant NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA16.10 Clinical Utility of Cerebrospinal Fluid Cell-Free DNA for Clarifying Genetic Features of Leptomeningeal Metastases in ALK Rearrangement NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Whole Brain Radiation Therapy Does Not Improve the Overall Survival of EGFR-mutant NSCLC Patients With Leptomeningeal Metastasis
Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients With Breast Cancer
Molecular and Cellular Proteomics
Biochemistry
Medicine
Analytical Chemistry
Molecular Biology
OA07.03 Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC PTS With Oligometastatic or Oligoprogressive Liver Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-60 Preventing and Treating Brain Metastases With Three First-Line EGFR-TKI in Patients With EGFR Mutation Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases
Scientific Reports
Multidisciplinary
MA08.06 Outcomes Among Patients With EGFR-Mutant Metastatic NSCLC With and Without Brain Metastases
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary